Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Masimo target raised to $95 at Wedbush — Flu season remains elevated, bodes well for MASI's 1Q17 results (88.53)Wedbush raises their MASI tgt to $95 from $85. Flu activity remains elevated, which could have positive implications for Masimo's 1Q17 results. Historically, severe flu seasons have led to a higher-than-average number of flu related hospitalizations, which tends to bode well for MASI's pulse oximetry franchise. This was the case during 2012-2013 and 2014-2015 flu seasons, which had a positive impact on MASI's 1Q13 and 1Q15 results, respectively. Masimo is on the Wedbush Best Ideas List (BIL).</td> </tr></table>"